Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.43 is 64% above its 5-year average of -1.18, near the high end of its 5-year range (-1.46–-0.43).
56.35% above its 12-month average of -0.98.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.04.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 34 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.43
EARNINGS PER SHARE (EPS) AVG TTM
-0.98
EARNINGS PER SHARE (EPS) AVG 3Y
-1.10
EARNINGS PER SHARE (EPS) AVG 5Y
-1.18
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+56.35%
CURRENT VS 3Y AVG
+60.91%
CURRENT VS 5Y AVG
+63.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Neuronetics, Inc.
Market Cap
$153.79M
Earnings Per Share (EPS)
-0.43
TTM Avg
-0.98
3Y Avg
-1.10
5Y Avg
-1.18
Market Cap
$153.58M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.05
3Y Avg
-0.06
5Y Avg
-0.06
Market Cap
$152.72M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.22M
Earnings Per Share (EPS)
-0.90
TTM Avg
-1.19
3Y Avg
-2.61
5Y Avg
-1.83
Market Cap
$151.01M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.32
3Y Avg
-0.33
5Y Avg
-0.37
Market Cap
$149.36M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$148.73M
Earnings Per Share (EPS)
-12.04
TTM Avg
-8.05
3Y Avg
-55.02
5Y Avg
-123.25
Market Cap
$148.64M
Earnings Per Share (EPS)
-1.81
TTM Avg
-1.58
3Y Avg
-0.32
5Y Avg
-0.34
Market Cap
$159.14M
Earnings Per Share (EPS)
-1.02
TTM Avg
-0.60
3Y Avg
-1.87
5Y Avg
-1.57
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $153.79M | -0.43 | -0.98 | -1.10 | -1.18 |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | -0.05 | -0.06 | -0.06 |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.22M | -0.90 | -1.19 | -2.61 | -1.83 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -0.26 | -0.32 | -0.33 | -0.37 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -1.13 | -2.24 | -2.81 | -2.43 |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -12.04 | -8.05 | -55.02 | -123.25 |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -1.81 | -1.58 | -0.32 | -0.34 |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -1.02 | -0.60 | -1.87 | -1.57 |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | -0.51 | -0.38 | -0.76 | -1.59 |
Trailing EPS (TTM)
$-0.43
Forward EPS (Est.)
$-0.35
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.59 |
| 2024-12-31 | -1.38 |
| 2023-12-31 | -1.05 |
| 2022-12-31 | -1.38 |
| 2021-12-31 | -1.22 |
| 2020-12-31 | -1.46 |
| 2019-12-31 | -1.87 |
| 2018-12-31 | -2.69 |
| 2017-12-31 | -1431.28 |
| 2016-12-31 | -1001.25 |
